Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC
H. Lee Moffitt Cancer Center and Research Institute
H. Lee Moffitt Cancer Center and Research Institute
Essen Biotech
University of California, Irvine
Vall d'Hebron Institute of Oncology
Essen Biotech
Fred Hutchinson Cancer Center
H. Lee Moffitt Cancer Center and Research Institute
BGI, China